Document is current
Any future updates will be listed below
-
Authors
Wiley, Mark B.
Bauer, Jessica
Alvarez, Valentina
Kolics, Zoe
Cheng, Wenxuan
Church, David N.
Kerr, David J.
Kerr, Rachel S.
Jung, Barbara
-
Funding
Funding for this research was provided by:
NIHR Comprehensive Biomedical Research Centre (C26642/A27963)
National Institutes of Health (R01 CA141057)
- License Information
-
More Information
Article History
Received: 10 September 2024
Accepted: 24 February 2025
First Online: 12 March 2025
Declarations
:
: The authors declare no competing interests.
: Separate informed consent was obtained for use of tumor tissue and blood samples in the translational analyses. All patient data obtained from the QUASAR II clinical trial study was provided in a deidentified manner. The QUASAR II clinical trial was performed in accordance with the protocols Good Clinical Practice, European Directive 2001/20/ED and 2005/28/EC and the Declaration of Helinski. Study approval was obtained from the West Midlands Research Ethics Committee (Edgbaston, Birmingham, UK; REC reference: 04/MRE/11/18). All participants provided written informed consent for treatment, and separate consent was obtained for use of tumor tissue and blood samples in the translational analyses.
